ArticleMicrobiology spectrum2026
Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Feline infectious peritonitis virus (FIPV), a highly pathogenic subtype of feline coronavirus, is characterized by antigenic variability and immune evasion, resulting in limited efficacy of existing clinical therapeutic regimens. In recent years, ursodeoxycholic acid (UDCA), a hydrophilic bile acid derivative, has been found to have broad antiviral activity. Based on this, this study significantly improved the replication efficiency of FIPV by constructing a CRFK-PHBLV-N cell line that can stably express the FIPV N protein; UDCA had obvious antiviral effects, and signaling pathways related to UDCA's anti-FIPV activity were screened by transcriptome sequencing, and it was found that UDCA could significantly promote secretion of interferon-β by CRFK-PHBLV-N cells, activating the JAK-STAT signaling pathway and upregulating the expression of interferon-stimulated genes. This study revealed that FIPV escapes host immune response by inhibiting the JAK-STAT pathway, and UDCA was able to reverse this inhibition and enhance the expression of antiviral proteins, thus effectively inhibiting the replication and spread of FIPV. Furthermore, UDCA can also directly disrupt the envelope components of FIPV, inducing the disintegration of the viral structure. This study not only provides a new strategy for the efficient IMPORTANCE: In this study, through the establishment of a complete research chain of "virus titer-enhanced cell model-drug effect evaluation-signaling pathway analysis", we confirmed that ursodeoxycholic acid (UDCA) can inhibit feline infectious peritonitis virus (FIPV) infection and revealed that UDCA can activate the JAK-STAT signaling pathway by promoting the production of large amounts of interferon-β in host cells to protect against FIPV infection. It not only provides a new experimental tool (CRFK-PHBLV-N cell line) and drug candidate (UDCA) for FIP prevention and control, but also lays a theoretical foundation for the development of novel therapeutic strategies targeting the host antiviral pathway through the elucidation of the JAK-STAT pathway mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.